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ABSTRACT: Current methods for capturing circulating tumor
cells (CTCs) are based on the overexpression of cytokeratin (CK)
or epithelial cell-adhesion molecule (EpCAM) on cancer cells.
However, during the process of metastasis, tumor cells undergo
epithelial-to-mesenchymal transition (EMT) that can lead to the
loss of CK/EpCAM expression. Therefore, it is vital to develop a
capturing technique independent of CK/EpCAM expression on
the cancer cell. To develop this technique, it is important to
identify common secondary oncogenic markers overexpressed on
tumor cells before and after EMT. We analyzed the biomarker
expression levels in tumor cells, before and after EMT, and found
two common proteinshuman epidermal growth factor receptor 2
(Her2) and epidermal growth factor receptor (EGFR) whose levels remained unaffected. So, we synthesized immunomagnetic iron
nanocubes covalently conjugated with antibodies of Her2 or EGFR to capture cancer cells irrespective of the EMT status. The
nanocubes showed high specificity (6−9-fold) in isolating the cancer cells of interest from a mixture of cells spiked in serum. We
characterized the captured cells for identifying their EMT status. Thus, we believe the results presented here would help in the
development of novel strategies for capturing both primary and metastatic cancer cells from patients’ blood to develop an effective
treatment plan.
■ INTRODUCTION
Isolation of circulating tumor cells (CTCs) from the blood of
cancer patients and analyzing them enables the clinician to
predict the disease status, drug resistance, and the selection of
appropriate therapy. Food and Drug Administration (FDA)-
approved CellSearch is currently used for the detection of
CTCs in a variety of metastatic tumor types to predict the
overall survival and progression-free survival in patients.1 This
system utilizes magnetic microbeads coated with an antibody
(Ab) specific to epithelial cell-adhesion molecule (EpCAM)
for the enrichment of CTCs from the patient’s blood. Even
though these magnetic beads are beneficial and widely used in
clinics, the system has several drawbacks.2,3 Notably, the
system detects only EpCAM-positive CTCs and fails to
capture tumor cells with no epithelial markers.4
The tumor cells lose cytokeratin (CK) and EpCAM while
undergoing epithelial-to-mesenchymal transition (EMT), a
process that occurs during metastases.5,6 In fact, the loss of
these epithelial markers makes CTCs elastic, aiding cell
movement through the extracellular matrix of a tumor leading
to metastasis (Figure 1).7,8 Importantly, the transitioned CTCs
with no epithelial markers provide crucial information about
the metastasis and effective treatment options.9−12 Therefore,
it is vital to develop a capturing technique independent of CK/
EpCAM expression on the cancer cell. The technique based on
microfluidics for sorting cells has been developed for capturing
mesenchymal cells.13 Attempts have been made to increase the
efficiency of the microfluidic system by combining with
immunomagnetic beads.14,15 The ideal system to efficiently
capture the EMT transitioned cells is still lacking.
One possible way to capture the cells with high efficiency is
to develop immunomagnetic beads that are selective, in
capturing both epithelial and mesenchymal cancer cells, and
powerful by selectively removing the cells from the milieu. To
develop a selective immunomagnetic bead, we need to identify
the common biomarkers overexpressed on tumor cells before
and after EMT. Therefore, we analyzed the biomarker
expression levels in tumor cells, before and after EMT, and
found two common proteinshuman epidermal growth factor
receptor 2 (Her2) and epidermal growth factor receptor
(EGFR), whose levels remained unaffected. On the other
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hand, to develop a powerful immunomagnetic bead, we need
particles with high magnetic moment. Traditional sphere-
shaped magnetic beads have a magnetic moment of 5−40
emu/g.16−20 The magnetic moment can be increased by
decreasing the size of beads or changing the spherical shape to
a cube.17,21,22 For example, nanosized spherical particles (∼40
nm) show magnetic moment >40 emu/g, whereas the cube-
shaped nanoparticles of the same size exhibit higher magnetic
moment than the spherical counterparts.22 Therefore, in the
present study, we have developed smaller sized nanocubes
attached with biomarkers expressed in EMT cells and studied
their efficacy in cell capture.
Briefly, we followed a two-pronged approach for the
isolation of cancer cells. First, we synthesized paramagnetic
20 nm iron oxide nanocubes (FeNCs) with a high magnetic
moment of 65 emu/g. Second, we conjugated antibodies to the
particles to obtain immunomagnetic iron nanocubes. We chose
Her2 (ERBB2) and EGFR (ERBB1) antibodies for function-
alizing the nanocubes as they play critical roles in regulating
Figure 1. (a) Schematic illustration of the migration of tumor cells
after undergoing EMT and (b) regulators and markers of the EMT
process in tumor cells and metastatic abilities.
Figure 2. (a) Schematic diagram of the preparation of iron oxide nanocube constructs; magnetic properties for FeNC (b) superconducting
quantum interference device (SQUID) hysteresis; (c) zero-field curve; (d) schematic illustration of iron nanocubes conjugated to the antibody;
and (e) transmission electron microscopy (TEM) images of (i) hydrophilic FeNC, (ii) PEGylated FeNC, (iii) FeNC−Her, and (iv) FeNC−EGF.
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EMT.23,24 It is anticipated that their expression levels often
remain unaffected in the cancer cells.25−28 Using the cube-
shaped nanoparticles, we developed a highly efficient
immunomagnetic platform, functionalized with antibodies,
for the isolation of cancer cells with or without epithelial
markers. We avoided the conventional strategy of using gold or
silica shell over the magnetic particles, which can potentially
decrease the magnetic moment of the final construct.29,30
Instead, we employed poly(maleic anhydride)-based ring-
opening strategy to generate carboxylic functional groups that
allow covalent conjugation with biomarker-specific antibodies,
as well as increase the hydrophilicity and solubility of the
FeNC.
We analyzed the expression levels of biomarkers that are
retained and overexpressed on the membrane of cancer cells
before and after EMT. The expression levels of Her2 or EGFR
were confirmed to remain unaffected, before and after EMT
stimulation in cancer cells. Targeting these biomarkers,
unaffected by EMT, would allow us to capture cancer cells
irrespective of the expression of epithelial antigens.10−12 Before
the EMT process is fully complete, there is an intermediary
stage known as partial EMT that may express both EMT
regulators such as Her2/EGFR and also epithelial antigens.31
At this stage, both Her2 and EGFR are activated, resulting in
overexpression in the cell surface. However, epithelial antigen
levels may fluctuate depending on the environment.32,33
Therefore, combining an anti-epithelial marker and anti-
Her2/EGFR markers with nanocubes may present an efficient
approach to capture all CTC subpopulations in a given sample.
In this article, we present the results of the following studies:
(i) synthesis and characterization of FeNC functionalized with
Her2 or EGFR antibodies; (ii) evaluation of the expression
levels of biomarkers in cancer cells before and after EMT; (iii)
determination of FeNC’s ability to capture epithelial and
mesenchymal cancer cells; and (iv) evaluation of epithelial
markers in captured cells.
■ RESULTS AND DISCUSSION
Synthesis and Characterization of Magnetic Nano-
cubes. We synthesized FeNC by thermal decomposition (295
°C) of iron−acetylacetonate complex that generates Fe3+ ions
that are reduced by polyol to produce nanocrystalline seeds
(Figure 2a). By carefully maintaining the growth conditions,
we obtained uniform nanocubes with an edge length of 20 nm.
The cubic shape imparted a higher magnetic moment of 65
emu/g (Figure 2b,c), relative to previously known spherical
nanoparticles, which showed 40−50 emu/g.21,22 In compar-
ison, magnetic beads of size 0.2−1 mm exhibit a saturation
magnetization of 10−25 emu/g.17 Commercially available
Dynabeads show a magnetic moment of 12 emu/g.18 The
magnetic moment data obtained for FeNC synthesized in this
study is similar to previously reported iron nanocubes.34 The
synthetic protocol used in this study facilitates the transition of
ferromagnetic to paramagnetic FeNC crystals;34 consequently,
the nanoparticles are in a nonmagnetized form in the absence
of an externally applied field. This characteristic property
enhances the utilization of FeNCs in cell capture and selective
isolation. Additionally, nanocubes exhibit high surface area,
excellent binding capacity, and higher analytical sensitivity as
compared to traditional spherical nanoparticles.35
As synthesized, the FeNCs coated with oleic acid are
hydrophobic and inefficient in capturing cells under aqueous
conditions. Therefore, we modified the surface of the particles
with hydrophilic molecules to impart water solubility. Recent
studies have utilized amphiphilic molecules such as poly-
(maleic anhydride-alt-1-octadecene) (PMAOD) for making
nanoparticles water-soluble (Figure 2a).36,37−40 Importantly,
PMAOD adds functional −COOH groups to the nanoparticles
for conjugating with antibodies.36 We replaced the oleic acid
on the surface of FeNC with PMAOD and, subsequently,
hydrolyzed the rings of maleic anhydride to obtain carboxylic
groups (Figure 2a). Further, to prevent the interparticle
attraction of FeNCs, which lead to agglomerates, we
introduced “poly(ethylene glycol) (PEG)” molecules as a
stabilizing linker. The chosen PEG linker “NH2-PEG-COOH”
(molecular weight (MW) 2000) increased the interparticle
dispersity (Figure 2a,d).41 Additionally, as the PEG linker
contains terminal carboxylic groups, the total available carboxyl
groups per nanoparticle remain unchanged before and after
PEGylation. We used N-(3-dimethylaminopropyl)-N′-ethyl-
carbodiimide hydrochloride (EDC)−N-hydroxysuccinimide
(NHS) coupling agent for conjugating PEGylated FeNCs
with antibody (Ab) of our choice (Figure 2a,d). It is important
to ascertain that the specificity of the antibody is retained after
conjugating with PEGylated FeNC. We chose the “antiglobin
and globin” to validate the specificity by enzyme-linked
immunosorbent assay (ELISA), wherein we conjugated the
antibody of globin with PEGylated FeNC and globin as an
analyte (Figure S1). The ELISA data showed that the FeNC−
Ab−globin construct displayed a linear correlation toward the
antigen concentration, confirming that the antibody retains its
specificity upon conjugation. Based on the encouraging results,
we conjugated FeNC with Her2 or EGFR antibodies for
evaluating their ability to capture cancer cells that overexpress
the respective receptors.
As a next step, we characterized all of the synthesized
nanoparticles using conventional analytical techniques. TEM
images of hydrophilic FeNC, PEGylated FeNC, and FeNC−
Ab constructs showed the uniform shape of the particles
(Figures 2e and S2). FeNC−Ab constructs are stable in
aqueous solutions and showed a hydrodynamic size of ∼175
nm with a negative ζ potential (Table 1 and Figure S3).
Biomarker Selection for Cell Capture. The overex-
pressed growth factor receptors, Her2 and EGFR, are
considered to be the essential drivers for cell proliferation
and regulation of EMT.23−25,27 To identify if Her2 or EGFR
can be used as suitable biomarkers for targeting and isolating
cancer cells after EMT, we investigated the expression levels of
growth receptors in multiple cancer cells by Western blot
(WB) analysis. In this study, we selected three cancer cell lines,
namely, A549, HCC827, and MCF-7. We isolated the lysates
and performed WB analysis and the results are shown in Figure
3a. The data showed that A549 expresses high levels of both
Table 1. Size and ζ Potential Characteristics for the As-
Synthesized Hydrophilic FeNC, PEGylated FeNC, and
Antibody-Attached, FeNC−Her and FeNC−EGF
construct
hydrodynamic size
(d, nm)
ζ
(mV)
TEM edge length
(nm)
hydrophilic
FeNC
148 −63 20
PEGylated FeNC 142 −5.8 20
FeNC−Her 171 −6.5 20
FeNC−EGF 175 −5.8 20
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Her2 and EGFR, with Her2 showing 1.6 times higher
expression than EGFR; HCC827 expresses high EGFR (3.9
times higher than Her2 relatively) and low Her2, whereas
MCF-7 expresses high levels of Her2 and no expression of
EGFR. The expression levels agreed with previously published
studies.25−28 Therefore, for Her2-based capturing of cells, we
used A549 as a positive and HCC827 as a negative control. On
the other hand, for EGFR-based cell capture, we used
HCC827 as a positive and MCF-7 as a negative control.
Expression Levels of Protein Markers in EMT-
Stimulated Cancer Cells. As a next step, we artificially
stimulated EMT in our positive target cell lines (A549 and
HCC827) to monitor the changes in expression levels of EMT
markers, epithelial antigens, Her2, and EGFR proteins. We
used TGFβ-1 and EGF to induce EMT in both A549 and
HCC827.42,43 As shown in Figure 3b, within 72 h, the cells lost
their epithelial adhesion on the substrate and transformed into
an invasive elongated state confirming EMT stimulation. The
lysates from these EMT-stimulated cells were then analyzed
using WB (Figure 3c). The data showed increased expression
levels of vimentin in both the cell lines after the induction of
EMT (increase of 171% in A549 and 53% in HCC827). The
upregulation of vimentin is characteristic of mesenchymal
cells,44 and the result further validates successful EMT
stimulation in cells. As shown in previous studies, we also
observed a decrease in expression levels of most cytokeratins
(CK; −31% in A549 and −12% in HCC827) and EpCAM
epithelial markers (−73% in A549 and −82% in HCC827) in
the EMT-induced cells.5,6,25,27,44 A slight decrease in Her2
expression levels (−20%) in A549 cells was observed after
EMT, whereas the EGFR expression levels increased in both
A549 and HCC827 EMT cells (67 and 52%, respectively).
Based on the data, it is evident that both Her2 and EGFR can
serve as biomarkers; therefore, their antibodies can be utilized
for capturing A549 and HCC827 cells, respectively, before and
after EMT transformation. Indeed, previous studies have also
shown that both Her2 and EGFR biomarkers play crucial roles
in regulating EMT and also overexpressed during the
process.23−25,27 Thus, targeting these two biomarkers allows
the cell capture to be more efficient and independent of their
EMT status (CK and EpCAM levels).
Magnetic Nanocubes for Capturing Epithelial Cancer
Cells. We first investigated the selectivity of the FeNC−Her
and FeNC−EGF to capture epithelial cancer cells. As per our
WB analysis, A549 showed a high expression of both Her2 and
EGFR. Therefore, we hypothesized that the FeNC−Her or
FeNC−EGF would be able to capture A549 cells selectively;
while HCC827 showed only the EGFR expression, we
postulated that only FeNC−EGF would be able to capture
HCC827 cells. To test the hypotheses, we prepared a mixture
Figure 3. (a) Western blot images showing the native expression levels of EGFR and Her2 in A549, HCC827, MCF-7 cells, and its corresponding
band densitometry plot. (b) Morphological changes during EMT conversion for 0−72 h in A549 cells. After EMT conversion, the cells appear
more elongated in shape compared to untreated (Figure S4). Images were taken using bright-field microscopy at a 10× magnification, and the scale
bar represents 200 μm. (c) Western blot images showing changes in the expression levels of proteins in A549 and HCC827 cells before and after
induction of EMT, and its corresponding band densitometry plot.
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of A549 and HCC827 in equal proportions and independently
labeled with different color dyes (for example, A549 with a red
membrane dye, while HCC827 with a blue nuclear dye).
Subsequently, we used FeNC−Ab constructs to capture cells
for isolation by magnetic separation. The cells were then
counted by fluorescence and identified by the corresponding
color (Figure 4; see the Methods section).
To isolate a maximum number of cells, we optimized two
crucial parameters: antibody coating on FeNC and particulate
concentrations of FeNC required for isolation. For evaluating
the first parameter, we used FeNC with varying degrees of Ab
on the surface and treated with the sample containing 100 cells
of each cell line (Figure 5). We anticipated that increased Ab
concentrations (1×, 6×, and 20× Ab) would increase the
specificity of cell capture. That is, FeNC conjugated with a
high concentration of herceptin (anti-Her2) should capture
A549 cells with a higher degree of specificity. Similarly, FeNC
conjugated with high concentrations of cetuximab (anti-
EGFR) should capture both A549 and HCC827 with no
preference for either one. As shown in Figure 5, the increase in
Ab coating directly correlated with the number of cells
captured. The data showed that the efficiency of FeNC−Her
to capture A549 cells increased from 4- to 8-fold, while for
FeNC−EGF to capture A549 or HCC827 cells increased from
4.3- to 7-fold or 3- to 9-fold, respectively. These results
indicate the high selectivity of FeNC in capturing cancer cells
based on the target receptor expression. For evaluating the
second parameter, we treated different concentrations of
FeNC−Her or FeNC−EGF or FeNC (control) with a cell
mixture of 104 cells per cell line, and the results are presented
in Figure 5. In this experiment, we performed cell capture with
varying amounts of NPs, and the results are presented in
Figure 5. The data for FeNC−Ab showed a proportional
increase in capture (2- to 3-fold) with an increase in particle
concentration. The data also showed a 3-fold increase in
capture selectivity for FeNC−Ab constructs as compared to
that for the FeNC control at higher concentrations. The results
indicated that a minimum concentration of 2 × 106 particles/
mL would be required to achieve high sensitivity in capturing
cells without increasing nonspecific binding counts. Together,
the data established the ability of FeNC−Ab to precisely
capture cancer cells based on their target expression.
Magnetic Nanocubes for Capturing Epithelial Cancer
Cells in Serum. As a next step, we evaluated the ability of
antibody-conjugated FeNC constructs to capture cancer cells
spiked in serum to simulate clinical sampling conditions. In
this study, we used FeNC (control), FeNC−Her, and FeNC−
EGF for selective capturing of A549 and HCC827 cells
independently. The cells were spiked in serum isolated from
pig blood. Both FeNC−Her and FeNC−EGF successfully
captured cells according to the receptor expression levels in
A549 and HCC827 (Figure 6). As expected, the FeNC control
showed negligible capture (Figure 6). Our results showed that
FeNC−Her was highly specific and efficient in capturing A549
cells than HCC827 cells as compared to FeNC−EGF (92 vs
55%), while FeNC−EGF was more active in detecting
HCC827 cells. The fold-change between FeNC−Her and
FeNC−EGF in capturing A549 cells was about 3-fold, while
the specificity of FeNC−EGF over FeNC−Her in capturing
HCC827 was almost 4-fold. These data suggested that FeNC−
Her was an ideal candidate for capturing A549, while FeNC−
EGF was a candidate to capture HCC827 cells. Additionally,
the data indicated that magnetic nanocubes were stable in
capturing cells in serum and exhibit similar specificity and
selectivity as that of aqueous solutions. Such studies with the
Her/EGFR-targeted capture based on heterogeneous expres-
sion in cells have been previously demonstrated.45
Subsequently, we conducted a specificity test for FeNC−Her
and FeNC−EGF in capturing positive target cells relative to
control from a cell mixture in serum. For this experiment, we
used samples spiked with an A549−HCC827 1:1 mixture
(from 102 to 104 cells per cell line), wherein A549 was a
Figure 4. Steps in the immunomagnetic FeNC-mediated capture and isolation of cancer cells.
Figure 5. Capture selectivity and sensitivity of nanoparticles with
increased (a, b) antibody coating on the surface and (c, d) particle
concentrations on a 1:1 mixture of A549−HCC827 cells. Cells
separated using immunomagnetic FeNC exhibit high specificity and
sensitivity.
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positive control for FeNC−Her, and HCC827 was a negative
control. Similarly, we tested a sample spiked with HCC827−
MCF-7 mixture (from 102 to 104 cells per cell line), wherein
HCC827 was a positive control for FeNC−EGF, and MCF-7
was a negative control. Our results indicated a successful
capture and isolation of cells by the constructs over their
controls (Figure 7). Data showed a specificity difference of 9-
and 6-folds for FeNC−Her and FeNC−EGF, respectively, in
capturing positive cells instead of negative control cells at the
lowest cell spike. In both cases, the nonspecific capture by
FeNC (control) was insignificant (<2%) compared to that of
FeNC−Ab constructs. Similar results in a previous study with
magnetic liposomes showed higher specificity when EGFR was
targeted compared to EpCAM.46 Another group showed that
targeting Her2 and EGFR can complement and enhance
epithelial marker-based targeting methods.47 In summary, the
data demonstrated the ability of FeNC to capture cancer cells
based on the antibody−receptor specificity to oncogenic
surface receptors such as Her2 or EGFR in serum.
Magnetic Nanocubes for Capturing Mesenchymal
Cancer Cells in Serum. To test the ability of FeNC−Her and
FeNC−EGF in capturing mesenchymal A549 and HCC827
cells, we spiked the EMT-induced cells in serum (along with
negative HCC827 or MCF-7 epithelial cells) and analyzed the
capture counts (Figure 8). We followed the fluorescent
labeling strategy as described above to count the cells.
FeNC−Her showed excellent capturing ability with A549
cells before and after EMT induction (Figure 8). In fact,
FeNC−Her showed higher efficiency in capturing most of the
cells after EMT. Similarly, FeNC−EGF also showed
remarkable capturing ability before and after EMT conversion
of HCC827 cells. If the sample contains ≤10 cells, we
observed background noise and more significant deviations in
the capture. However, data was consistent within the range
tested (10, 50, and 100 spiked cells per each type). The data
established the capability of FeNC−Her and FeNC−EGF in
capturing cancer cells irrespective of their EMT status. These
results are in agreement with a previous study where targeting
mesenchymal cells by EMT-marker was 2.1-fold efficient than
targeting epithelial markers.48 In another study, the magnetic
beads targeting EGFR were found to be 80% more efficient
than targeting epithelial markers in a low EpCAM expressing
cell line.49 Together, the data strengthens the use of growth
receptors such as Her2 or EGFR to capture mesenchymal cells.
Biomarker Characterization of Captured Cells. As a
final step, we investigated the surface epithelial marker status of
the captured cells. We performed fluorescent immunostaining
using an anti-CK antibody (tagged with Alexa Flour 647) in
the epithelial and mesenchymal captured cells (Figure 9a).
Then, we analyzed the difference between the total cells
captured and the cells that showed positive-CK staining
(Figure 9b,c). A549 cells captured by FeNC−Her showed a
62.5% decrease in cells expressing CK after EMT stimulation
(p < 0.047). Similarly, HCC827 cells captured by FeNC−EGF
showed a 75% decrease in cells expressing CK after induction
of EMT (p < 0.005). The drastic decrease in epithelial marker
Figure 6. Demonstration of (a, b) the receptor-based capture using
102 or 103 cells and (c) construct specificity to A549 vs HCC827 in
serum solution.
Figure 7. Specificity capture tests between (a, b) FeNC−Her and
FeNC (nonspecific capture) for A549−HCC827 mixed spiked
samples and (c, d) FeNC−EGF and FeNC (nonspecific capture)
for HCC827−MCF-7 mixed spiked samples.
Figure 8. Cell capture before and after induction of EMT in (a, b)
A549−HCC827 mixture and (c, d) HCC827−MCF-7 mixture by
FeNC−Her and FeNC−EGF, respectively. EMT in A549 and
HCC827 cells were stimulated, respectively.
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expression in cells confirmed that the captured cells are of
mesenchymal type. Further, we showed that magnetic
nanocubes capture and allow the detection of cytokeratin
status in the captured cells. The ability to characterize
biomarkers in captured cells is an essential step in developing
technologies for clinical applications.50−53 In summary, our
results demonstrate that FeNC−Her and FeNC−EGF
constructs could successfully capture, isolate, and allow the
detection of epithelial marker status in captured cells.
■ CONCLUSIONS
We developed a novel magnetic nanocube-based tumor-cell
capture technique for separating epithelial and/or mesenchy-
mal cells. In this study, we have shown that surface markers
such as Her2 and EGFR are unaffected by the EMT state and
are potential biomarkers for capturing CTCs. The magnetic
nanocubes can help in isolating specific cancer cells based on
their marker and allow the detection of EMT and non-EMT
population subsets within a given pool of cells. The results of
this study underscore the importance of using growth receptors
as a secondary target for capturing CTCs. As the tumor is
always heterogeneous, the proposed method provides an
opportunity to capture CTCs that express variable biomarkers.
The results present in this study can aid in developing next-
generation techniques for CTC isolation in clinics.
■ METHODS
Materials. We purchased iron(III) acetylacetonate, oleic
acid, benzyl ether, poly(maleic anhydride-alt-1-octadecene)
(PMAOD), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide
hydrochloride (EDC), N-hydroxy sulfosuccinimide sodium salt
(sulfo-NHS), 2-(N-morpholino)ethane sulfonic acid (MES),
bovine serum albumin (BSA), MS-SAFE protease and
phosphatase inhibitor, Triton X-100, Tween-20, and phos-
phate-buffered saline (PBS) from Sigma-Aldrich. Hexane,
toluene, and chloroform were purchased from Acros Organics.
Sodium hydroxide (NaOH), acetone, sucrose, sodium borate
buffer, Hoechst dye, CellMask deep red membrane dye, Pierce
ECL Western blotting substrate, Pierce BCA protein assay kit,
and 3,3′,5,5′-tetramethylbenzidine (TMB) were purchased
from Thermo Fisher Scientific. β-Actin, vimentin, EpCAM,
cytokeratin primary antibody kit (7, 8, 17, 18, 19, PAN),
EGFR, Her2, and both antimouse and antirabbit secondary
horseradish peroxidase (HRP)-linked immunoglobulin G
(IgG) antibodies were purchased from Cell Signaling.
Carboxylic-poly(ethylene glycol)-amine was custom-synthe-
sized from Nanocs and Laysan Bio. 10× Tris-buffered saline
(TBS), 10× Tris/glycine/sodium dodecyl sulfate (SDS) buffer,
4−15% 10-well 50 μL ready Mini-Protean TGX, Precision Plus
Protein dual-color standard ladder, and supported nitro-
cellulose membrane (0.2 μm) were purchased from Bio-Rad.
Recombinant human EGF (carrier-free) and Alexa Fluor 647
tagged anticytokeratin PAN antibody were purchased from
BioLegend. Recombinant human transforming growth factor
β-1(TGFβ-1) and EGF were purchased from Novoprotein.
Amicon 0.5 mL of 100 kDa regenerated cellulose ultracel
centrifugal filter units were purchased from Merck Millipore
Ltd. Cetuximab (Eli Lilly and Company) and herceptin
(Genetech Inc.) were purchased from the hospital pharmacy.
Instrumentation. High-resolution JEOL transmission
electron microscope (TEM) was used to measure and record
the images of nanoparticles. The hydrodynamic size and ζ
potential of the nanoparticles were measured using a Malvern
Zetasizer Nano-ZS (Malvern Panalytical). The centrifugation
was performed on a 5424 Eppendorf and refrigerated RC 6+
Sorvall centrifuge (Thermo Fisher Scientific). The pH was
measured using a Seven Compact Mettler Toledo pH meter
equipped with an InLab Micro electrode. We performed
fluorescence imaging, fluorescence, and UV−vis absorption
measurements using a Cytation 5 cell imaging multi-mode
reader (BioTek Instruments Inc.). Gel electrophoresis was
performed on a Bio-Rad Mini-PROTEAN Tetra system, and
blots were transferred using a Genscript e-blot transfer system.
We performed Western blot imaging and acquisition using
Image Lab version 5.2.1 software on a ChemiDoc XRS system
from Bio-Rad. Solvent extraction was performed on a Büchi
rotavapor R-124 attached to a water bath and water-cooled
distillation column. Finally, SQUID measurements were
performed on a Quantum Design MPMS 3 magnetometer
(Quantum Design).
Synthesis of Iron Oxide Nanocubes. We synthesized
iron oxide nanocubes (FeNCs) using a high-temperature
polyol reduction process in an organic phase. Briefly, a
modified protocol based on previous studies was used for
synthesizing particles.34,54 In this procedure, iron(III)
acetylacetonate (7.06 g, 20 mmol) was added to a mixture of
oleic acid (1.129 g, 12.69 mL) and benzyl ether (104 g, 99.71
mL) in a three-neck 200 mL round-bottom flask (RBF)
attached to a reflux condenser and a Schlenk line. This solution
was degassed using Argon (20 kPa) for 1 h under constant
stirring (400 rpm), and the reaction was kept under argon
throughout the process. After initial degassing, the reaction
temperature was increased to 295 °C at a heating rate of 20
°C/min under constant stirring (500 rpm). The reaction color
turned jet black from reddish brown after 30 min, and at this
stage, the solution temperature decreased to 100 °C. Next, the
solution was then quickly cooled on ice and a mixture (80 mL)
of hexane, toluene, and acetone with a ratio of 1:1:2 was
added. This solution was stirred and sonicated to remove
particles stuck to the stir bar. The solution was then transferred
to a 500 mL beaker with a seal and allowed to precipitate for
15 h. The top solution was decanted, and the remaining
solution containing the precipitate was centrifuged at 20 000g
for 1 h (15 °C). The pellet was then resuspended and washed
several times using a mixture of hexane and toluene (ratio of
Figure 9. (a) Steps for EMT stimulation and magnetic separation;
and staining and detection of cytokeratin in cells captured by (b)
FeNC−Her and (c) FeNC−EGF.
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1:1) until a slight clear supernatant formed. For each wash, the
tube was kept over a neodymium magnet (pull force of 250 lb)
for 15 min followed by the slow removal of the supernatant
using a 10 mL pipette. This solution was then concentrated in
hexane and washed five times (15 000g for 15 min) until a
clear supernatant formed. Finally, the particles (20 mg yield)
were resuspended in 4 mL of hexane and stored at room
temperature.
Hydrophilic Conversion of Iron Oxide Nanocubes.
The iron nanocubes synthesized using the polyol process
resulted in the formation of hydrophobic particles. To convert
them to hydrophilic particles for use in aqueous and
physiological solutions, we replaced the organic coating with
a functional amphiphilic polymer by modifying a previously
published protocol.36 Briefly, synthesized FeNCs (in hexane)
were injected into a rapidly stirring (500 rpm) poly(maleic
anhydride-alt-1-octadecene) (1.2 g, average molecular weight
30 000−50 000) solution dissolved in chloroform (100 mL) in
a one-neck 200 mL RBF. After 2 h of stirring, the solvent was
removed using a rotary evaporator (100 rpm, 55 °C) attached
to a standard vacuum line protected by a liquid nitrogen cool
trap, until a wet sludge was formed. The sludge was quickly
mixed with 50 mL of 0.1 M NaOH solution and dispersed by
sonicating for 1 h. The solution was then stirred (500 rpm) for
15 h at room temperature to hydrolyze and open the maleic
anhydride rings. The solution was washed twice with 0.1 M
NaOH solution at 20 000g (15 °C) for 1 h, followed by
washing twice with a three-layer sucrose density gradient
centrifugation (30, 20, and 10% sucrose). The pellet was
resuspended and concentrated in 4 mL of 10 mM MES buffer
and washed once. As a next step, 100 kDa centrifugal filters
were equilibrated with MES buffer and used for removing
excess polymer (6000g for 6 min). The solution was then again
subject to a two-layer sucrose density gradient centrifugation
(30 and 10% sucrose) at 15 000g for 15 min, followed by six
washes with DI water. The FeNC pellet was then dispersed in
5 mL water and stored at room temperature.
Synthesis of PEGylated Nanocubes. To enhance the
stability and solubility in aqueous solutions, the carboxyl
groups of hydrophilic particles were activated using EDC/
sulfo-NHS and conjugated with NH2-PEG-COOH. Briefly, the
particles were dissolved in 0.1 M MES buffer (pH 4.5)
containing 2 mg EDC and 2 mg sulfo-NHS and kept for
shaking (850 rpm) for 1 h at 28 °C. The particles were then
centrifuged (15 000g for 15 min), and the pellet was dispersed
in a 50 mM sodium borate buffer containing 10 mg carboxylic-
poly(ethylene glycol)-amine (COOH-PEG-NH2, MW 2000; 5
μmol) and 5 mg EDC (26 μmol). This solution was kept
shaking (850 rpm) for 15 h at 22 °C. After the reaction,
PEGylated FeNCs were washed with water two times (15 000g
for 15 min), suspended in DI water, and stored at room
temperature. PEGylated FeNCs were used for conjugation
with antibodies.
Antibody Conjugation. We conjugated the antibody
(Ab) to the hydrophilic PEGylated FeNCs by the traditional
EDC/sulfo-NHS cross-linking procedure. Briefly, 100 μL (2 ×
106 particles/mL) of FeNCs was washed with 0.1 M MES
buffer (pH 4.5) prior to being activated. The pellet was
dispersed in 0.1 M MES buffer (400 μL; pH 4.5) with 3 mg
EDC (16 μmol) and 4 mg sulfo-NHS (18 μmol) at 28 °C for
3.5 h (shaking at 800 rpm). After activation, the particles were
centrifuged (15 000g for 15 min), dispersed in 100 μL 1× PBS,
and mixed with the antibody solution of either 4 μL of globin−
Ab (10 mg/mL), 200 μL of herceptin (2 mg/mL), or 200 μL
of cetuximab (2 mg/mL). The reaction was kept in a shaker
(800 rpm) for 15 h at 22 °C and, upon completion, washed
twice with 1× PBS (15 000g for 15 min). The final solution
was dispersed in 1 mL of 1× PBS and stored at 4 °C. The
FeNC−Ab−globin was used for estimating the protein
conjugation efficiency using the known globin protein, while
FeNC conjugated to cetuximab and herceptin was used to
target EGFR and Her2 in cell studies. These particles were
labeled as FeNC−EGF and FeNC−Her, respectively. Due to
the ready availability of globin−Ab, we were able to estimate
the conjugation efficiency using ELISA and anticipate that the
conjugation efficiency of antibodies of EGF and Her to FeNC
would be similar to that of globin−Ab to FeNC.
Characterization of Magnetic Nanocubes. We charac-
terized FeNC using TEM and dynamic light scattering (DLS)
technique. For TEM, 8 μL of 1/10th diluted FeNCs was
placed over a CF300-Cu carbon film-based copper grid and air-
dried for 10 min in a hot air oven (40 °C). TEM imaging for
polymer-coated and PEGylated FeNCs showed a uniform size
of 20 nm. For DLS measurements, 1 mL of 1/10th diluted
FeNC solution was placed in a disposable UV-grade cuvette
and analyzed. The magnetic properties were further inves-
tigated using the superconducting quantum interference device
(SQUID) analysis. For this analysis, 5 mg of the lyophilized
FeNC power was loaded in sealed SQUID sample holders. The
magnetic moment was recorded using the temperature
sweeping mode under zero-field-cooled (ZFC) conditions
from 2 to 300 K at 1000 Oe. The corrected magnetic moment
was then determined by a previously published procedure.55
ELISA. To determine the conjugation efficiency of the
antibody bound to FeNC, we used an indirect enzyme-linked
immunosorbent assay (ELISA). For this experiment, the
FeNC−Ab−globin construct was used to evaluate the
specificity to globin antigen; the reaction-supernatant was
used to quantify the amount of conjugated globin antibody.
PEGylated FeNCs were used as the negative control, and PBS
was considered as the blank. Briefly, 100 μL of globin solution
(0.1, 1, 10, and 100 μg/mL, respectively) was added to wells of
a flat-bottom sterile 96-well plate and left undisturbed for 15 h
at 4 °C. The wells were then washed with a wash buffer (0.5%
Tween-20) followed by blocking with 200 μL of 2% BSA
solution for 30 min at room temperature. As a next step, the
wells were washed with a wash buffer prior to the addition of
samples (100 μL). After 2 h, at 37 °C, the sample solutions
were washed with a wash buffer. Subsequently, 50 μL of the
0.32 μg/mL secondary antibody (goat antirabbit IgG-HRP)
was then added to the wells and incubated for 30 min at 37 °C
followed by two washes with a wash buffer. Finally, 50 μL of
the substrate solution (TMB peroxidase) was added to the
wells and the reaction was stopped by adding 0.1 M HCl
solution. The plates were then read by a Cytation 5 absorbance
plate reader at 450 nm, and the absorption intensity was
correlated to the concentration of the globin antibody
conjugated to FeNC.
SQUID Magnetic Analysis. We evaluated the magnetic
properties of FeNCs using superconducting quantum interfer-
ence device (SQUID) equipped with a 7 T magnet. In this
process, Josephson junctions were used to measure a change in
the magnetic flux using a coil with a known inductance. For the
magnetometry analysis, 5 mg of pure lyophilized FeNCs was
loaded in a VSM sample holder. Measurements were made
using a five-quadrant magnetic moment with varying external
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magnetic field analysis (Hmax of 5 T at T = 2 K). Zero-field-
cooled magnetic susceptibility and field-cooled warming
measurements were performed using a sweep mode from 2
to 300 K at 1000 Oe. Using this analysis, the blocking
temperature was estimated. Raw data was then corrected for
sample shape and radial offsets and graphs were plotted.
Isolation of Blood Serum. Pig serum was obtained from
an investigator at the University of Missouri for the spiking
studies. Protocols in accordance with the ethical animal-
handling regulations as approved by the University of Missouri
were followed. Five milliliters of blood was collected from pigs
in a sealed test tube. The clotted blood was centrifuged (100g
for 10 min at 4 °C), and the serum was isolated and stored at 4
°C. The serum was used for cancer cell spiking experiments.
Cell Culture. A549, HCC827, and MCF-7 human cancer
cell lines (ATCC) were grown in the Roswell Park Memorial
Institute (RPMI) 1640 medium (obtained from Gibco BRL).
The media was supplemented with 4.5 g/L D-glucose, 25 mM
N-(2-hydroxyethyl)piperazine-N′-ethane sulfonic acid
(Hepes), 0.11 g/L sodium pyruvate, 1.5 g/L sodium
bicarbonate, 2 mM L-glutamine, 10% heat-inactivated fetal
bovine serum (FBS; Atlanta Biologicals), and 1% penicillin/
streptomycin antibiotic solution. The cells were cultured in a
humidified atmosphere of 95% air and 5% CO2 at 37 °C
(Thermo Scientific).
EMT Conversion. To induce epithelial-to-mesenchymal
transition (EMT) artificially in cells, 120 ng of TGFβ (20 ng/
mL) and 60 ng of EGF (10 ng/mL) protein were mixed in 6
mL serum-free media and treated with A549 cells. Treatment
was performed at 60% confluence in a T25 flask for 72 h in a
CO2 incubator. Flasks were monitored every 24 h using a
bright-field microscope, and images were obtained. At the end
of the conversion, the flask was washed once with fresh RPMI
media containing 10% FBS and twice with cold 1× PBS. The
cells were then dislodged and used for magnetic capture.
Capture and Detection of Cancer Cells. To capture and
detect spiked cancer cells, we developed a robust magnetic
extraction process. In this experiment, the cells selected for
capture and detection were either A549 (Her2+++, EGFR++)
or HCC827 (EGFR+++), while control cells were either
HCC827 (EGFR+++) or MCF-7 (Her2+++), respectively.
For capturing the cells of interest, A549 or HCC827 cells with
or without EMT treatment (induced by TGFβ-1 and EGF)
were dislodged from the T25 flask (70% confluence) and used
for spiking experiment.42,43 For all experiments, target cells
such as A549 or HCC827 were live-stained red, while control
cells such as HCC827 or MCF-7 were live-stained blue. The
addition of control cells allows us to test the specificity of the
construct in each study. Additionally, all capture experiments
relied on live cells, while cytokeratin detection was performed
on fixed cells. Briefly, the cells were suspended in 1× PBS and
incubated with 40 μL of Hoechst (blue) dye or 40 μL of
CellMask (deep red stain) for 20 min at 37 °C. The cells were
washed with 1× PBS twice to remove excess dye (2000 rpm
for 5 min). The cells were counted, and cell stock solution was
prepared (102/103 or 104 cells). Two hundred microliters of
cell suspension (102/103 or 104 cells) was mixed with 200 μL
of control cells (102/103 or 104 cells, respectively) and placed
in a tube. Equal amounts of each target and control cell were
also placed in separate tubes as nontreated control. For testing
fixed concentration, 200 μL of the antibody-functionalized
FeNC construct (FeNC−Her or FeNC−EGF; 2 × 106
particles/mL) was added to the tube with cells and incubated
at 37 °C for 2 h (gently shaken every 5 min). For evaluating
varying concentrations, either the surface−antibody concen-
tration on nanoparticles (1× (0.4 mg/reaction), 6×, and 20×)
or nanoparticle concentration (1 × 106 or 2 × 106 particles/
mL) was changed. Following the treatment, the tubes were
placed (0.1 cm spacing) next to an N50-grade neodymium
block magnet (with a surface field of 4833 G, a dipole moment
(m) of 75.6 A m2, and a permeance coeff. Pc of 1.25) for 30
min. The supernatant was carefully removed, and the captured
pellet was washed twice with 500 μL of 1× PBS using magnetic
separation. The FeNC−Ab−cell solution was then resus-
pended in 200 μL of 1× PBS and transferred to a flat-bottom
96-well plate. To prevent any agglomeration, a hydrophobic
low retention 200 μL tip was used to quickly mix and transfer
without immersing the tip fully in solution. Cell counting of
stained cells was performed using an automated fluorescence-
based cell counter using the Cytation 5 imaging plate reader.
Western Blot. To perform Western blotting (WB), A549,
HCC827, or MCF-7 cells (1 × 106) with or without EMT
treatment at 70% confluence were seeded in six-well plates.
The cells were treated in serum-free media for a period of 72 h
followed by whole-cell lysate preparation using lysis buffer
containing 1× phosphatase inhibitor cocktail. Proteins were
separated by 4−15% polyacrylamide gel electrophoresis
(PAGE) and were transferred onto a nitrocellulose membrane
for protein blot analysis. Membranes were washed with 1×
TBST, blocked with a 5% BSA blocking buffer containing 0.5%
normal goat serum (NGS) for 2 h, and incubated with a
primary antibody overnight on a shaker at 4 °C. Blots were
then washed before and after incubation with a secondary
antibody and developed with the chemiluminescence system.
Densitometry analysis was performed using Image Studio Lite
software (LI-COR Biosciences).
Detection of Cytokeratin. To detect epithelial marker
status, the cells captured by antibody-functionalized FeNC
constructs (FeNC−Her or FeNC−EGF) were stained
(Hoechst dye) and fixed by adding 500 μL of 4%
paraformaldehyde for another 10 min at 37 °C. Next, 500
μL of 0.1% Triton X-100 was added and incubated for 5 min
after staining and fixing. The rest of the steps were the same for
the FeNC treatment. After cell capture and washing once with
1× PBS, 500 μL of 5% FBS solution in 1× PBS was added as a
blocking agent for 30 min. After the removal of a blocking
agent, 400 μL of Alexa Fluor 647 anticytokeratin antibody (2
μg/mL) solution diluted in 1× PBS cells was added to the tube
and incubated for 2 h at room temperature. The cells were
then washed twice with 1× PBS and then resuspended in 200
μL of 1× PBS. This solution was then quickly transferred to a
96-well plate for imaging and fluorescence-based cell counting
using the Cytation 5 imaging plate reader.
Statistics. All statistics were performed using Minitab. The
average values from triplicates were calculated and used for
statistical analysis. Statistical significance was evaluated using
Student’s t test, and p < 0.05 was considered significant.
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